





years, with an additional time up to a year to complete evaluation activities. Projects with a duration shorter than three years may be submitted; however, applicants are strongly urged to commit to realistic start dates to allow for time for recruitment and any necessary regulatory approvals. Projects must have a start time no later than 31 March 2024 to be eligible.

## Funding

Total funding for each award will be capped at a maximum allocation of £200,000. The total amount of funding requested, once approved by RMP following a successful interview by the Review Panel, will be awarded to the lead applicant host organisation in a detailed funding award letter in the 2023/2024 financial year. The host organisation will be required to accept the total award for the duration of the project, therefore written confirmation of support from the lead

breakdown of costs will be requested at the full application stage, using the template provided.

### Eligible costs

The RMP Research and Innovation Fund is funded from the NHS monies awarded to the Cancer Alliance to deliver on the aims of the LTP. Therefore, RMP will not pay for indirect costs, such as overheads, living costs or journal subscriptions. RMP will pay for the direct incurred cost of the project, including salaries of staff involved in the project, public and patient engagement activities, consumables, equipment (capped at £1,000), travel and dissemination costs. Applications where the primary intent is to purchase capital equipment will not be considered.

## Equality and Health Inequalities Impact Assessment

NHS England and NHS Improvement produced the Equality and Health Inequalities Impact Assessment (EHIA) to support the decision-making process in relation to all NHS programmes, and specifically in relation to the LTP. Applicants must articulate how their proposed project will contribute to improving existing health inequity.



